Cancer antigen 19-9 (CA 19-9)


Coşkun A, Aarsand AK, Sandberg S, Guerra E, Locatelli M, Díaz-Garzón J, Fernandez-Calle P, Ceriotti F, Jonker N, Bartlett WA, Carobene A, 2021, Clin Chem Lab Med, Online ahead of print, , Within- and between-subject biological variation data for tumor markers based on the European Biological Variation Study


Total Score


Parameter Score
1. Scale A
2. Study Population A
3. Samples A
4. Measurand A
5. Pre-Analytical A
6. Replicate Analysis A
7. Steady State A
8. Outlier Analysis A
9. Normality A
10. Variance Homogeneity A
12. CI A
13. No of Results A
14. Concentrations A
15. Total Score A1,2,3,4,5,6,7,8,9,10,11,12,13,14

Item Details

Parameter Score
Matrix Serum
Measurand Cancer antigen 19-9 (CA 19-9)
Unit ku / L
Overall Analytical Principle Method Immunoassay; Not specified
Number of Subjects 40
Number of Subjects included in BV estimation 40
Ethinicity Caucasian
Age Mean / Median
Age Min 21.0
Age Max 69.0
Age SD
Number of Males
Number of Females 40
State of Well Being
Healthy (excl pregnant)
Study Duration Length 10
Study Duration Units Week
Sampling Intervals, e.g. X sample(s) per Interval Unit 1
Interval Units Week
Sampling Times Start Time: 08:00
End Time: 10:00
Number of Samples 10
Average Number of Samples Used for BV Estimation 10.0
Average Number of Replicates 2.0
Estimates of CVi 4.1
Calculated Confidence Intervals of CVi Lower: 3.77, Upper: 4.47
Estimates of CVg 58.1
Calculated Confidence Intervals of CVg Lower: 47.69, Upper: 74.35
Analytical CV 2.3
Calculated Confidence Intervals of Analytical CV Lower: 2.15, Upper: 2.47
Measurand Mean 10.4
Measurand Min 9.9
Measurand Max 10.8
Measurand SD